EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.
Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, Leighl NB, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, Liu G.
Martins-Filho SN, et al. Among authors: weiss j.
Lung Cancer. 2020 Jul;145:144-151. doi: 10.1016/j.lungcan.2020.03.022. Epub 2020 May 11.
Lung Cancer. 2020.
PMID: 32447118